MX370546B - Derivados de bencimidazol y composiciones farmaceuticas de los mismos, para el tratamiento de trastornos inflamatorios. - Google Patents
Derivados de bencimidazol y composiciones farmaceuticas de los mismos, para el tratamiento de trastornos inflamatorios.Info
- Publication number
- MX370546B MX370546B MX2016009442A MX2016009442A MX370546B MX 370546 B MX370546 B MX 370546B MX 2016009442 A MX2016009442 A MX 2016009442A MX 2016009442 A MX2016009442 A MX 2016009442A MX 370546 B MX370546 B MX 370546B
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- treatment
- pharmaceutical compositions
- inflammatory disorders
- benzimidazole derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención describe compuestos de acuerdo con la Fórmula I: (ver Fórmula) en el que Cy, R1, L1, R3, R4, R5, La, y Ra están de acuerdo con lo definido en esta descripción. Se revelan nuevos bencimidazoles de acuerdo con la Fórmula I, capaces de inhibir la JAK, estos compuestos se pueden preparar como una composición farmacéutica, y se pueden utilizar para la prevención y el tratamiento de una variedad de afecciones en mamíferos que incluyen seres humanos, que incluyen a modo de ejemplo no limitativo, enfermedades alérgicas, enfermedades inflamatorias, enfermedades autoinmunes, enfermedades proliferativas, rechazo de trasplantes, enfermedades que implican un deterioro del recambio de los cartílagos, malformaciones congénitas de los cartílagos, y/o enfermedades asociadas con la hipersecreción de IL6 o la hipersecreción de interferones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1401086.2A GB201401086D0 (en) | 2014-01-23 | 2014-01-23 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2015/050850 WO2015110378A1 (en) | 2014-01-23 | 2015-01-19 | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016009442A MX2016009442A (es) | 2016-10-13 |
| MX370546B true MX370546B (es) | 2019-12-17 |
Family
ID=50287405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009442A MX370546B (es) | 2014-01-23 | 2015-01-19 | Derivados de bencimidazol y composiciones farmaceuticas de los mismos, para el tratamiento de trastornos inflamatorios. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9440929B2 (es) |
| EP (2) | EP3395802A1 (es) |
| JP (1) | JP6472454B2 (es) |
| CN (1) | CN106132934B (es) |
| AR (1) | AR099160A1 (es) |
| AU (1) | AU2015208269B2 (es) |
| BR (1) | BR112016016732B1 (es) |
| CA (1) | CA2941474A1 (es) |
| CY (1) | CY1120679T1 (es) |
| DK (1) | DK3097083T3 (es) |
| EA (1) | EA029827B1 (es) |
| ES (1) | ES2693019T3 (es) |
| GB (1) | GB201401086D0 (es) |
| HR (1) | HRP20181332T1 (es) |
| HU (1) | HUE039450T2 (es) |
| IL (1) | IL246823B (es) |
| LT (1) | LT3097083T (es) |
| MX (1) | MX370546B (es) |
| MY (1) | MY180363A (es) |
| NZ (1) | NZ723313A (es) |
| PH (1) | PH12016501677B1 (es) |
| PL (1) | PL3097083T3 (es) |
| PT (1) | PT3097083T (es) |
| SG (1) | SG11201606971XA (es) |
| SI (1) | SI3097083T1 (es) |
| TW (1) | TWI689496B (es) |
| WO (1) | WO2015110378A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR105400A1 (es) | 2015-08-04 | 2017-09-27 | Lilly Co Eli | Inhibidores de jak1 |
| NZ748942A (en) | 2016-07-14 | 2020-08-28 | Lilly Co Eli | Pyrazolylaminobenzimidazole derivatives as jak inhibitors |
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
| CN108355618B (zh) * | 2018-02-27 | 2020-09-08 | 江南大学 | 牛来源透明质酸酶亲和介质及其吸附方法 |
| CN108776121B (zh) * | 2018-04-08 | 2021-07-30 | 广州卡马生物科技有限公司 | 一种基于荧光猝灭原理对药材中抗氧剂的高通量筛选方法 |
| WO2020061086A2 (en) * | 2018-09-18 | 2020-03-26 | Terns, Inc. | Compounds for treating certain leukemias |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| GB201904373D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders |
| CN114671858B (zh) * | 2022-03-07 | 2023-08-08 | 华中师范大学 | 一种苯并咪唑系化合物及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1759203A2 (en) | 2004-06-21 | 2007-03-07 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
| EP2226315A4 (en) * | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-AMINOQUINAZOLINE DERIVATIVE |
| JP2011518219A (ja) * | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| WO2012044090A2 (ko) * | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| UY34615A (es) * | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. |
-
2014
- 2014-01-23 GB GBGB1401086.2A patent/GB201401086D0/en not_active Ceased
-
2015
- 2015-01-19 MX MX2016009442A patent/MX370546B/es active IP Right Grant
- 2015-01-19 CN CN201580015662.9A patent/CN106132934B/zh active Active
- 2015-01-19 US US14/599,644 patent/US9440929B2/en active Active
- 2015-01-19 EP EP18177201.3A patent/EP3395802A1/en not_active Withdrawn
- 2015-01-19 SG SG11201606971XA patent/SG11201606971XA/en unknown
- 2015-01-19 WO PCT/EP2015/050850 patent/WO2015110378A1/en active Application Filing
- 2015-01-19 NZ NZ72331315A patent/NZ723313A/en not_active IP Right Cessation
- 2015-01-19 MY MYPI2016702630A patent/MY180363A/en unknown
- 2015-01-19 LT LTEP15701945.6T patent/LT3097083T/lt unknown
- 2015-01-19 SI SI201530383T patent/SI3097083T1/sl unknown
- 2015-01-19 EA EA201691468A patent/EA029827B1/ru not_active IP Right Cessation
- 2015-01-19 JP JP2016548110A patent/JP6472454B2/ja active Active
- 2015-01-19 PL PL15701945T patent/PL3097083T3/pl unknown
- 2015-01-19 BR BR112016016732-5A patent/BR112016016732B1/pt active IP Right Grant
- 2015-01-19 CA CA2941474A patent/CA2941474A1/en not_active Abandoned
- 2015-01-19 PT PT15701945T patent/PT3097083T/pt unknown
- 2015-01-19 HU HUE15701945A patent/HUE039450T2/hu unknown
- 2015-01-19 EP EP15701945.6A patent/EP3097083B1/en active Active
- 2015-01-19 DK DK15701945.6T patent/DK3097083T3/en active
- 2015-01-19 AU AU2015208269A patent/AU2015208269B2/en not_active Ceased
- 2015-01-19 ES ES15701945.6T patent/ES2693019T3/es active Active
- 2015-01-22 TW TW104102159A patent/TWI689496B/zh active
- 2015-01-22 AR ARP150100176A patent/AR099160A1/es unknown
-
2016
- 2016-07-18 IL IL246823A patent/IL246823B/en active IP Right Grant
- 2016-08-23 PH PH12016501677A patent/PH12016501677B1/en unknown
- 2016-09-12 US US15/262,097 patent/US10179771B2/en active Active
-
2018
- 2018-08-22 HR HRP20181332TT patent/HRP20181332T1/hr unknown
- 2018-08-23 US US16/110,353 patent/US20190152922A1/en not_active Abandoned
- 2018-09-11 CY CY181100950T patent/CY1120679T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501677B1 (en) | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX355653B (es) | Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| NZ722403A (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| PH12017501921A1 (en) | Novel compounds | |
| MX2020003368A (es) | Sal de acido maleico de {5-[4-(1,1-dioxo-tiomorfolin-4-ilmetil)-fe nil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida del acido ciclopropancarboxilico. | |
| PH12020550230A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12014502615A1 (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
| MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
| NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| PH12017501160A1 (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| JO3030B1 (ar) | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات | |
| AR089960A1 (es) | Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias | |
| NZ709041A (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| MY182353A (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| PH12019501853A1 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| UA105796C2 (uk) | Сполука, застосовна для лікування дегенеративних і запальних захворювань | |
| MX2016009250A (es) | Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |